Verification with the utility of an established rapid assessment of brain safety for newly developed vaccines.
Identifieur interne : 000339 ( PubMed/Checkpoint ); précédent : 000338; suivant : 000340Verification with the utility of an established rapid assessment of brain safety for newly developed vaccines.
Auteurs : Gwang-Ho Kim [Corée du Sud] ; Sun Shin Yi [Corée du Sud]Source :
- Laboratory animal research [ 1738-6055 ] ; 2019.
Abstract
In the twenty-first century, high contagious infectious diseases such as SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), FMD (Foot-and-Mouth Disease) and AI (Avian Influenza) have become very prevalent, causing treat harm to humans and animals in aspect of public health, and economical issues. The critical problem is that newly-reported infectious diseases that humans firstly experience are expected to continue to emerge, and these diseases will be spreading out rapidly. Therefore, rapid and safe supplies of effective vaccines are most pivotal to prevent the rapid prevalent of new infection, but international standards or assessing protocol the safety of urgent vaccines are not established well. In our previous study, since we established a module to assess the brain safety of urgent vaccines, therefore, it is necessary to verify that this established module for assessing brain safety could work effectively in commercially available two vaccines (one killed- and on live-vaccines). We compared the results of Evans blue (EB) assay and qPCR analysis by injection of two kinds of vaccines, PBS and Lipopolysaccharide (LPS) under the condition of the module previously reported. We confirmed that the brain safety test module for urgent vaccine we established is very reproducible. Therefore, it is believed that this vaccine safety testing method can be used to validate brain safety when prompt supply of a newly developed vaccines is needed.
DOI: 10.1186/s42826-019-0027-8
PubMed: 32219059
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32219059Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Verification with the utility of an established rapid assessment of brain safety for newly developed vaccines.</title><author><name sortKey="Kim, Gwang Ho" sort="Kim, Gwang Ho" uniqKey="Kim G" first="Gwang-Ho" last="Kim">Gwang-Ho Kim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan, 31538 Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan</wicri:regionArea><wicri:noRegion>Asan</wicri:noRegion></affiliation></author><author><name sortKey="Yi, Sun Shin" sort="Yi, Sun Shin" uniqKey="Yi S" first="Sun Shin" last="Yi">Sun Shin Yi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan, 31538 Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan</wicri:regionArea><wicri:noRegion>Asan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:32219059</idno><idno type="pmid">32219059</idno><idno type="doi">10.1186/s42826-019-0027-8</idno><idno type="wicri:Area/PubMed/Corpus">000124</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000124</idno><idno type="wicri:Area/PubMed/Curation">000124</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000124</idno><idno type="wicri:Area/PubMed/Checkpoint">000339</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000339</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Verification with the utility of an established rapid assessment of brain safety for newly developed vaccines.</title><author><name sortKey="Kim, Gwang Ho" sort="Kim, Gwang Ho" uniqKey="Kim G" first="Gwang-Ho" last="Kim">Gwang-Ho Kim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan, 31538 Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan</wicri:regionArea><wicri:noRegion>Asan</wicri:noRegion></affiliation></author><author><name sortKey="Yi, Sun Shin" sort="Yi, Sun Shin" uniqKey="Yi S" first="Sun Shin" last="Yi">Sun Shin Yi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan, 31538 Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan</wicri:regionArea><wicri:noRegion>Asan</wicri:noRegion></affiliation></author></analytic><series><title level="j">Laboratory animal research</title><idno type="ISSN">1738-6055</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the twenty-first century, high contagious infectious diseases such as SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), FMD (Foot-and-Mouth Disease) and AI (Avian Influenza) have become very prevalent, causing treat harm to humans and animals in aspect of public health, and economical issues. The critical problem is that newly-reported infectious diseases that humans firstly experience are expected to continue to emerge, and these diseases will be spreading out rapidly. Therefore, rapid and safe supplies of effective vaccines are most pivotal to prevent the rapid prevalent of new infection, but international standards or assessing protocol the safety of urgent vaccines are not established well. In our previous study, since we established a module to assess the brain safety of urgent vaccines, therefore, it is necessary to verify that this established module for assessing brain safety could work effectively in commercially available two vaccines (one killed- and on live-vaccines). We compared the results of Evans blue (EB) assay and qPCR analysis by injection of two kinds of vaccines, PBS and Lipopolysaccharide (LPS) under the condition of the module previously reported. We confirmed that the brain safety test module for urgent vaccine we established is very reproducible. Therefore, it is believed that this vaccine safety testing method can be used to validate brain safety when prompt supply of a newly developed vaccines is needed.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32219059</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1738-6055</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Laboratory animal research</Title><ISOAbbreviation>Lab Anim Res</ISOAbbreviation></Journal><ArticleTitle>Verification with the utility of an established rapid assessment of brain safety for newly developed vaccines.</ArticleTitle><Pagination><MedlinePgn>25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s42826-019-0027-8</ELocationID><Abstract><AbstractText>In the twenty-first century, high contagious infectious diseases such as SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), FMD (Foot-and-Mouth Disease) and AI (Avian Influenza) have become very prevalent, causing treat harm to humans and animals in aspect of public health, and economical issues. The critical problem is that newly-reported infectious diseases that humans firstly experience are expected to continue to emerge, and these diseases will be spreading out rapidly. Therefore, rapid and safe supplies of effective vaccines are most pivotal to prevent the rapid prevalent of new infection, but international standards or assessing protocol the safety of urgent vaccines are not established well. In our previous study, since we established a module to assess the brain safety of urgent vaccines, therefore, it is necessary to verify that this established module for assessing brain safety could work effectively in commercially available two vaccines (one killed- and on live-vaccines). We compared the results of Evans blue (EB) assay and qPCR analysis by injection of two kinds of vaccines, PBS and Lipopolysaccharide (LPS) under the condition of the module previously reported. We confirmed that the brain safety test module for urgent vaccine we established is very reproducible. Therefore, it is believed that this vaccine safety testing method can be used to validate brain safety when prompt supply of a newly developed vaccines is needed.</AbstractText><CopyrightInformation>© The Author(s) 2019.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Gwang-Ho</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan, 31538 Republic of Korea.</Affiliation><Identifier Source="ISNI">0000 0004 1773 6524</Identifier><Identifier Source="GRID">grid.412674.2</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Sun Shin</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0001-8568-0954</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Laboratory Science, Soonchunhyang University, Asan, 31538 Republic of Korea.</Affiliation><Identifier Source="ISNI">0000 0004 1773 6524</Identifier><Identifier Source="GRID">grid.412674.2</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lab Anim Res</MedlineTA><NlmUniqueID>101560684</NlmUniqueID><ISSNLinking>1738-6055</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brain</Keyword><Keyword MajorTopicYN="N">Infectious disease</Keyword><Keyword MajorTopicYN="N">Public health</Keyword><Keyword MajorTopicYN="N">Rapid assessment</Keyword><Keyword MajorTopicYN="N">Vaccine safety</Keyword></KeywordList><CoiStatement>Competing interestsThe authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32219059</ArticleId><ArticleId IdType="doi">10.1186/s42826-019-0027-8</ArticleId><ArticleId IdType="pii">27</ArticleId><ArticleId IdType="pmc">PMC7081575</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
<ReferenceList><Reference><Citation>Neurochem Res. 2008 May;33(5):833-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17940875</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Neuropharmacol. 2008 Sep;6(3):179-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19506719</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochim Biophys Acta. 2008 Mar;1778(3):770-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18028872</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Vet Sci. 2013;14(4):373-80</Citation><ArticleIdList><ArticleId IdType="pubmed">23628656</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Vet Sci. 2018 Jul 31;19(4):505-511</Citation><ArticleIdList><ArticleId IdType="pubmed">29695143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Death Differ. 2009 Dec;16(12):1590-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19816508</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Vet Sci. 2017 Aug 31;18(S1):371-379</Citation><ArticleIdList><ArticleId IdType="pubmed">28859273</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Metab. 2015 Dec 1;22(6):962-70</Citation><ArticleIdList><ArticleId IdType="pubmed">26603190</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Neuroinflammation. 2015 Nov 25;12:223</Citation><ArticleIdList><ArticleId IdType="pubmed">26608623</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Vet Sci. 2018 Nov 30;19(6):750-758</Citation><ArticleIdList><ArticleId IdType="pubmed">30173495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2002 May 15;20 Suppl 2:S5-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12110248</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Epidemiol Community Health. 2006 Mar;60(3):192-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16476746</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 1998 Nov 6;273(45):29745-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9792688</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trends Neurosci. 2001 Dec;24(12):719-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11718877</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Histol Histopathol. 2004 Apr;19(2):607-28</Citation><ArticleIdList><ArticleId IdType="pubmed">15024719</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Neurobiol Dis. 2004 Jun;16(1):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15207256</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Neurosci Lett. 2013 Sep 13;551:23-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23876253</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Cell Biol. 2012 Jan;32(2):242-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22083955</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Pharmacol. 2009 Dec;9(6):715-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19632896</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Oxid Med Cell Longev. 2015;2015:120641</Citation><ArticleIdList><ArticleId IdType="pubmed">26290681</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Physiol Rev. 2013 Apr;93(2):525-69</Citation><ArticleIdList><ArticleId IdType="pubmed">23589827</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Pharm Biotechnol. 2012 Jun;13(7):1346-59</Citation><ArticleIdList><ArticleId IdType="pubmed">22201587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li></country></list><tree><country name="Corée du Sud"><noRegion><name sortKey="Kim, Gwang Ho" sort="Kim, Gwang Ho" uniqKey="Kim G" first="Gwang-Ho" last="Kim">Gwang-Ho Kim</name></noRegion><name sortKey="Yi, Sun Shin" sort="Yi, Sun Shin" uniqKey="Yi S" first="Sun Shin" last="Yi">Sun Shin Yi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000339 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000339 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32219059
|texte= Verification with the utility of an established rapid assessment of brain safety for newly developed vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32219059" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |